Michael Norsen

Vice President, Alexandria LaunchLabs NYC & Alexandria Venture Investments

2024 - Current

Principal, Alexandria Venture Investments

2020 - 2024

Head of LaunchLabs @ Columbia - NYC

2020 - 2024

Head of Strategic Partnerships at the Regeneron Genetics Center (RGC)

2018 - 2020

A wholly owned subsidiary of Regeneron Pharmaceuticals, the Regeneron Genetics Center (RGC) is focused on partnering with academic medical centers and health systems throughout the world to sequence and jointly analyze patient cohorts in order to identify new genetic targets that are driving disease. In this role, Michael is responsible for leading and scaling the strategic partnering and business development organization within the RGC to meet the organization's strategic and operational growth goals.

Head of Business Operations and Strategic Planning at the Regeneron Genetics Center (RGC)

2015 - 2018

A wholly owned subsidiary of Regeneron Pharmaceuticals, the Regeneron Genetics Center (RGC) is focused on partnering with academic medical centers and health systems throughout the world to sequence and jointly analyze patient cohorts in order to identify new genetic targets that are driving disease. In this role, Michael was responsible for the building, growing and optimizing the business development, strategic planning, financial management as well as the operations and alliance management functions for the RGC.

Manager, Alliance Management & Strategic Business Planning, CTI

2011 - 2015

The Centers for Therapeutic Innovation (CTI) is an innovative collaboration model, supported by Pfizer that partners with investigators at academic medical centers (AMCs) worldwide to accelerate the translation of novel biomedical insights from the lab to the clinic. In this role, Michael planned, launched, and maintained strong alliance relationships as primary liaison with 25 world class academic medical centers (AMC) and 4 non-profit patient foundations across 4 major markets within the CTI network. Michael also lead and/or contributed to due diligence, negotiation, execution and governance of collaborations across an array of therapeutic areas. In addition, Michael held additional responsibilities in finance & operations as well as market analytics and commercial development.

Business Analyst

2008 - 2011

Business Analyst, Strategic CRM Group, Global Procurement and Operations (GPO) 03/10 – 04/11 Aligned Procurement strategies to support the Biopharmaceutical and Diversified Commercial Business Units (BUs) by examining commercial strategies and internal business needs. Led data gathering, analytics, and business case-generation for multiple BU opportunity analyses. Conducted and presented financial analysis on each commercial BU to Procurement and BU Finance Leadership team to identify innovative sourcing opportunities. Business Analyst, Professional Services, Worldwide Procurement (WWP) 11/08 – 03/10 Developed analytical models and reporting procedures for global consulting and legal spend. Conducted and presented financial analysis of worldwide consulting spend to CFO and ELT on quarterly basis. Led all quantitative and qualitative analyses to support the sourcing process for global consulting efforts to provide supplier selection recommendations to key stakeholders and drive future negotiation strategies related to Wyeth Integration.

BioPharma Supply Chain Analyst

2006 - 2008

Lead analyst that implemented and optimized a supply chain strategy for Enbrel®, a joint venture with Amgen that was Wyeth’s leading commercial biologic product. Planned the global supply chain for the company’s leading Phase III Alzheimer’s product.

Strategic Sourcing Analyst

2006 - 2006

Led cross-functional team that developed a long-term model to continuously manage sterilization capacity for the company’s portfolio of commercial products.